Protein tyrosine phosphatases in multiple myeloma
Abstract: Many cell signaling pathways are activated or deactivated by protein tyrosine phosphorylation and dephosphorylation, catalyzed by protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs), respectively. Even though PTPs are as important as PTKs in this process, their role has been neglected for a long time. Multiple myeloma (MM) is a cancer of plasma cells, which is characterized by production of monoclonal immunoglobulin, anemia and destruction of bone. MM is still incurable with high relapse frequency after treatment. In this review, we highlight the PTPs that were previously described in MM or have a role that can be relevant in a myeloma context. Our purpose is to show that despite the importance of PTPs in MM pathogenesis, many unanswered questions in this field need to be addressed. This might help to detect novel treatment strategies for MM patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
Cancer letters. - 501 (2021) , 105-113, ISSN: 1872-7980
- Ereignis
-
Veröffentlichung
- (wo)
-
Freiburg
- (wer)
-
Universität
- (wann)
-
2021
- Urheber
- Beteiligte Personen und Organisationen
-
Abteilung Integrative Signalforschung
- DOI
-
10.1016/j.canlet.2020.11.042
- URN
-
urn:nbn:de:bsz:25-freidok-2210903
- Rechteinformation
-
Kein Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:49 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Abdollahi, Pegah
- Köhn, Maja
- Børset, Magne
- Abteilung Integrative Signalforschung
- Universität
Entstanden
- 2021
Ähnliche Objekte (12)
Characterization of Novel Mutations in Receptor-Tyrosine Kinases in Multiple Myeloma
Multiple myeloma
Proteasome inhibition: the dawn of novel therapies in multiple myeloma
Is immunotherapy here to stay in multiple myeloma?
Novel immunotherapies in multiple myeloma – chances and challenges
Rare SNPs in receptor tyrosine kinases are negative outcome predictors in multiple myeloma
Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
Multiple myeloma is affected by multiple and heterogeneous somatic mutations in adhesion- and receptor tyrosine kinase signaling molecules
Compliance with vaccination recommendations among patients with multiple myeloma: a real world experience
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma
Prediction and verification of novel peptide targets of protein tyrosine phosphatase 1B
Characterization of Novel Mutations in Receptor-Tyrosine Kinases in Multiple Myeloma
Multiple myeloma
Proteasome inhibition: the dawn of novel therapies in multiple myeloma
Is immunotherapy here to stay in multiple myeloma?
Novel immunotherapies in multiple myeloma – chances and challenges
Rare SNPs in receptor tyrosine kinases are negative outcome predictors in multiple myeloma
Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
Multiple myeloma is affected by multiple and heterogeneous somatic mutations in adhesion- and receptor tyrosine kinase signaling molecules
Compliance with vaccination recommendations among patients with multiple myeloma: a real world experience
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma
Prediction and verification of novel peptide targets of protein tyrosine phosphatase 1B
Characterization of Novel Mutations in Receptor-Tyrosine Kinases in Multiple Myeloma
Multiple myeloma
Proteasome inhibition: the dawn of novel therapies in multiple myeloma
Is immunotherapy here to stay in multiple myeloma?
Novel immunotherapies in multiple myeloma – chances and challenges
Rare SNPs in receptor tyrosine kinases are negative outcome predictors in multiple myeloma
Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
Multiple myeloma is affected by multiple and heterogeneous somatic mutations in adhesion- and receptor tyrosine kinase signaling molecules
Compliance with vaccination recommendations among patients with multiple myeloma: a real world experience
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma